ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1929

The Neutrophil-Lymphocyte Ratio in Newly Diagnosed Rheumatoid Arthritis and Its Ability to Predict Treatment Failure

Daniel Boulos1, Robert Metcalf2, Susanna Proudman3 and Ian Wicks4, 1Rheumatology, Royal Melbourne Hospital, Melbourne, Melbourne, Australia, 2Rheumatology, Royal Adelaide Hospital, Adelaide, Adelaide, Australia, 3Royal Adelaide Hospital, Rheumatology Unit and University of Adelaide, Discipline of Medicine, Adelaide, Australia, 4Wicks Lab, Walter and Eliza Hall Institute, Melbourne, Australia

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: neutrophils, prognostic factors, rheumatoid arthritis (RA) and treatment guidlelines

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: 4M105 ACR Abstract: RA–DX, Manifestations, & Outcomes III: Diagnosis & Prognosis II (1929–1934)

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: To assess whether the neutrophil-lymphocyte ratio (NLR) can predict those who require disease modifying therapy escalation and hence progression in rheumatoid arthritis (RA).

Methods: Patients with newly diagnosed RA were recruited from the Early Arthritis Clinic at the Royal Adelaide Hospital. Those who were on glucocorticoids at the time of review were excluded. All patients were commenced on methotrexate, sulphasalazine and hydroxychloroquine and were reviewed at regular intervals, and Disease Modifying Anti-Rheumatic Drug (DMARD) therapy was adjusted according to a set algorithm. The NLR, platelet-lymphocyte ratio (PLR) and other markers of disease activity such as the ESR, CRP and DAS28 were collected as well as current therapy. The primary outcome measure was failure of triple DMARD therapy.

Results: Two-hundred and twenty-two patients met inclusion criteria. The mean age was 54.2±15.4 years with a mean duration of polyarthritis of 22.3±25.0 weeks prior to their first review. Forty-five (20%) of patients had failed triple therapy by one year. The mean NLR was significantly higher in those who failed triple therapy when compared to those that did not (3.7±2.8 vs 2.9±1.5; p=0.02), however, the PLR was not significantly different (184.1±78.6 vs 171.4±84.5; p=0.41). The NLR was an independent predictor of treatment failure (OR 2.65, CI 1.23-5.72, p=0.01) whilst the PLR, ESR, CRP and DAS-28ESR were not (p-values 0.41, 0.13, 0.17 and 0.28 respectively).

Conclusion: The NLR is significantly increased in those with treatment failure in RA and outperforms more conventional markers of disease activity. The NLR may be a cheap, objective and reproducible prognostic marker, however, further prospective studies are required to identify the role of the NLR in RA disease management algorithms.


Disclosure: D. Boulos, None; R. Metcalf, None; S. Proudman, Actelion Australia, 2,Actelion Australia, 8,Glaxo Smith Kline, 2; I. Wicks, None.

To cite this abstract in AMA style:

Boulos D, Metcalf R, Proudman S, Wicks I. The Neutrophil-Lymphocyte Ratio in Newly Diagnosed Rheumatoid Arthritis and Its Ability to Predict Treatment Failure [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/the-neutrophil-lymphocyte-ratio-in-newly-diagnosed-rheumatoid-arthritis-and-its-ability-to-predict-treatment-failure/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-neutrophil-lymphocyte-ratio-in-newly-diagnosed-rheumatoid-arthritis-and-its-ability-to-predict-treatment-failure/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology